0
Obstructive Lung Diseases: Safety and Effectiveness of COPD Treatments |

Improved COPD Control With Combination LABA/CS Using Small Volume Nebulized Delivery

Lydia Winnicka, MD; Jamie Molina, MD; Crystal Duran, MD; Charumathi Raghu Subramanian, MD
Author and Funding Information

Guthrie Clinic, Sayre, PA


Copyright 2016, American College of Chest Physicians. All Rights Reserved.


Chest. 2016;150(4_S):924A. doi:10.1016/j.chest.2016.08.1024
Text Size: A A A
Published online

Extract

SESSION TITLE: Safety and Effectiveness of COPD Treatments

SESSION TYPE: Original Investigation Slide

PRESENTED ON: Tuesday, October 25, 2016 at 11:00 AM - 12:15 PM

PURPOSE: There is a growing body of research supporting initiating long-acting β-agonist (LABA) therapy via small volume nebulization (SVN) in patients with uncontrolled COPD. Arformoterol SVN compared to a placebo has previously demonstrated a 40% lower risk of respiratory death or COPD-related hospitalization over 1 year, improvements in trough FEV1 and FVC, and improved quality of life via the St. George’s Hospital Respiratory Questionnaire and Clinical COPD Questionnaire.1 Arformoterol SVN has also shown to be superior as compared to short-acting β-agonist (SABA) SVN in preventing readmissions after hospitalization for COPD exacerbation.2 In patients with uncontrolled COPD, despite regular use of a combination LABA/corticosteroid (CS) inhaler, changing the medication delivery system to an SVN formulation is an option for better disease control. Hypothesized reasons for improved disease control with SVN formulations include ease of use and improved medication delivery. There is currently no data comparing inhaled LABA/CS versus the same medication via SVN.

First Page Preview

View Large
First page PDF preview

Sign In to Access Full Content

MEMBER & INDIVIDUAL SUBSCRIBER

Want Access?

NEW TO CHEST?

Become a CHEST member and receive a FREE subscription as a benefit of membership.

Individuals can purchase this article on ScienceDirect.

Individuals can purchase a subscription to the journal.

Individuals can purchase a subscription to the journal or buy individual articles.

Learn more about membership or Purchase a Full Subscription.

INSTITUTIONAL ACCESS

Institutional access is now available through ScienceDirect and can be purchased at myelsevier.com.

Sign In to Access Full Content

MEMBER & INDIVIDUAL SUBSCRIBER

Want Access?

NEW TO CHEST?

Become a CHEST member and receive a FREE subscription as a benefit of membership.

Individuals can purchase this article on ScienceDirect.

Individuals can purchase a subscription to the journal.

Individuals can purchase a subscription to the journal or buy individual articles.

Learn more about membership or Purchase a Full Subscription.

INSTITUTIONAL ACCESS

Institutional access is now available through ScienceDirect and can be purchased at myelsevier.com.

Figures

Tables

References

NOTE:
Citing articles are presented as examples only. In non-demo SCM6 implementation, integration with CrossRef’s "Cited By" API will populate this tab (http://www.crossref.org/citedby.html).

Some tools below are only available to our subscribers or users with an online account.

Sign In to Access Full Content

MEMBER & INDIVIDUAL SUBSCRIBER

Want Access?

NEW TO CHEST?

Become a CHEST member and receive a FREE subscription as a benefit of membership.

Individuals can purchase this article on ScienceDirect.

Individuals can purchase a subscription to the journal.

Individuals can purchase a subscription to the journal or buy individual articles.

Learn more about membership or Purchase a Full Subscription.

INSTITUTIONAL ACCESS

Institutional access is now available through ScienceDirect and can be purchased at myelsevier.com.

Related Content

Customize your page view by dragging & repositioning the boxes below.

Find Similar Articles
CHEST Journal Articles
  • CHEST Journal
    Print ISSN: 0012-3692
    Online ISSN: 1931-3543